Cambrex Announces Investment and Expansion to Large Scale, Multi-Purpose Manufacturing Capabilities at its Karlskoga, Sweden,...
September 06 2016 - 10:00AM
Cambrex Corporation (NYSE:CBM), the leading manufacturer of small
molecule innovator and generic Active Pharmaceutical Ingredients
(APIs), today announced a SEK 72 million ($9 million) investment to
expand large scale manufacturing capacity at its Karlskoga facility
in Sweden.
The investment includes the installation of new
multi-purpose reactors ranging from 4m3 to 12m3 and upgrading of
the control room within an existing plant on site. The new
facilities will undergo validation and cGMP qualification ahead of
the operational startup in Q4 2016. This extra capacity increases
the large scale manufacturing capabilities of the Karlskoga
facility, which supports clients’ development projects from R&D
through to large scale commercial manufacturing.
“Our facility at Karlskoga is strategically
important, both in Scandinavia and the wider European markets, and
this investment is in response to an increase in demand for larger
scale, multi-purpose manufacturing capabilities,” commented Bjarne
Sandberg, Managing Director, Cambrex Karlskoga. “By creating
greater capacity within the current infrastructure, we have
combined expansion and efficiency at the site, both of which will
benefit our customers.”
The expansion at Cambrex’s Swedish site is part
of an ongoing strategic campaign to invest in small molecule API
manufacturing across its global network of facilities.
About CambrexCambrex
Corporation is an innovative life sciences company that provides
products, services and technologies to accelerate the development
and commercialization of small molecule therapeutics. The Company
offers Active Pharmaceutical Ingredients (APIs), advanced
intermediates and enhanced drug delivery products for branded and
generic pharmaceuticals. Development and manufacturing capabilities
include enzymatic biotransformations, high potency APIs, high
energy chemical synthesis and controlled substances. For more
information, please visit www.cambrex.com.
Contact: Alex Maw
Director, Marketing and Communications
Phone: +44 7803 443 155
Email: alex.maw@cambrex.com
Cambrex (NYSE:CBM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cambrex (NYSE:CBM)
Historical Stock Chart
From Apr 2023 to Apr 2024